Drugs Containing Excipient (Inactive Ingredient) ALUMINUM HYDROXIDE

Branded drugs containing ALUMINUM HYDROXIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	COUMADIN	warfarin sodium	50090-0028	ALUMINUM HYDROXIDE
ITERUM THERAPEUTICS US LIMITED	ORLYNVAH	sulopenem etzadroxil and probenecid	81153-100	ALUMINUM HYDROXIDE	2034-10-25

Generic drugs containing ALUMINUM HYDROXIDE excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	diclofenac sodium	0228-2550	ALUMINUM HYDROXIDE
Actavis Pharma Inc	nystatin and triamcinolone acetonide	0472-0150	ALUMINUM HYDROXIDE
Par Pharmaceutical	nystatin	0603-7818	ALUMINUM HYDROXIDE
Major Pharmaceuticals	oxycodone hydrochloride	0904-6444	ALUMINUM HYDROXIDE

Aluminum Hydroxide Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 20, 2026

Aluminum hydroxide is a mature, low-cost pharmaceutical excipient with two distinct value pools: commodity antacid formulations and higher-specification vaccine adjuvants. Volume growth is modest, but revenue quality improves materially when suppliers sell GMP-controlled, particle-engineered grades for biologics, vaccines, and regulated oral suspensions. The molecule itself has limited patent protection because its core composition and principal pharmaceutical uses are longstanding. Commercial barriers instead arise from quality systems, particle-size control, impurity specifications, manufacturing validation, regulatory history, and customer qualification.

What is aluminum hydroxide used for in pharmaceuticals?

Aluminum hydroxide, CAS 21645-51-2, is used in pharmaceutical products as an antacid, adsorbent, stabilizer, and vaccine adjuvant. Its commercial form is not a single uniform material. Suppliers sell products with different crystallinity, hydration state, surface area, particle-size distribution, viscosity, adsorption capacity, and sodium or sulfate content.

Pharmaceutical use	Function	Main dosage or product category	Value profile
Antacid	Neutralizes gastric acid	Tablets, suspensions, gels	High volume, low to moderate margin
Vaccine adjuvant	Adsorbs antigen and enhances immune response	Injectable vaccines	Lower volume, higher margin and qualification burden
Adsorbent	Binds active ingredients or impurities	Oral and parenteral formulations	Application-specific
Stabilizer	Supports suspension stability	Liquid oral products	Formulation-dependent
Processing aid	Supports purification or adsorption	Selected biologics and intermediates	Specialized
Reference or analytical material	Quality-control testing	Laboratory use	Small volume, high unit price

Aluminum hydroxide is often described as “alum” in vaccine discussions, although alum can refer to several aluminum-containing adjuvant systems. Aluminum hydroxide adjuvant is distinct from aluminum phosphate and mixed aluminum salt formulations.

How large is the aluminum hydroxide pharmaceutical market?

No audited public database reports aluminum hydroxide pharmaceutical excipient revenue as a standalone global category. Market estimates are difficult to compare because commercial reports often combine pharmaceutical, vaccine, water-treatment, cosmetics, food, and industrial applications.

The pharmaceutical segment is best analyzed as two markets:

1. Oral antacid and suspension-grade aluminum hydroxide.
2. Injectable vaccine-adjuvant and biologics-grade aluminum hydroxide.

The first market is larger by volume. The second market is more attractive by gross margin and customer retention.

Market growth drivers

Demand is supported by:

• Continued use of aluminum hydroxide in generic antacid products.
• Growth in over-the-counter gastrointestinal medicines in emerging markets.
• Vaccine production, particularly for products using aluminum adjuvants.
• Outsourcing of excipient manufacturing by generic and specialty-pharmaceutical companies.
• Demand for validated, compendial, low-endotoxin materials.
• Expansion of local vaccine and pharmaceutical manufacturing capacity in Asia and other emerging markets.

Growth is constrained by:

• The mature nature of aluminum hydroxide antacid products.
• Substitution by calcium carbonate, magnesium hydroxide, sodium bicarbonate, and combination products.
• Regulatory scrutiny of elemental aluminum exposure.
• Limited dose expansion because aluminum hydroxide is used at low concentrations in many formulations.
• Qualification costs that slow switching between suppliers.

The market should be characterized as stable to moderately growing rather than high growth. Vaccine-grade products can grow faster than oral antacid grades, but their contribution to total volume remains smaller.

What are the main product grades and why do they affect margins?

Grade selection determines commercial value more than the chemical identity of the material.

Oral pharmaceutical grade

Oral grades typically require compliance with applicable USP-NF, Ph. Eur., or other pharmacopoeial standards. Buyers evaluate:

• Assay and aluminum content.
• Heavy metals and elemental impurities.
• Microbial limits.
• Particle-size distribution.
• Loss on drying and water content.
• Viscosity and sedimentation behavior.
• Acid-neutralizing capacity.
• Batch-to-batch reproducibility.

These products are relatively price-sensitive. Generic antacid manufacturers often qualify multiple sources when the formulation permits substitution.

Vaccine-adjuvant grade

Vaccine applications require tighter control over:

• Particle morphology.
• Surface charge and adsorption behavior.
• Endotoxin and bioburden.
• Sterility or sterile processing controls.
• Residual process chemicals.
• Antigen binding and release performance.
• Suspension stability.
• Container-closure compatibility.
• Manufacturing change control.

Adjuvant customers generally conduct extensive technical and regulatory qualification. Once a material is incorporated into a licensed vaccine, replacement can require comparability work, stability data, and regulatory engagement. This creates stronger retention and pricing power than in the antacid market.

Engineered and customized grades

Suppliers can increase value through controlled particle size, surface modification, concentration, and suspension properties. Custom grades may support a particular antigen, active ingredient, or delivery format. These products are less exposed to spot-market pricing and can produce better margins, although development and validation costs are higher.

Which companies supply pharmaceutical aluminum hydroxide?

The competitive field includes excipient manufacturers, vaccine-adjuvant specialists, chemical producers, and pharmaceutical distributors. Public company disclosures rarely report aluminum hydroxide revenue separately.

Relevant supplier groups include:

• Croda International’s Pharma business, including aluminum-based vaccine-adjuvant products associated with its Biosector activities.
• SPI Pharma, known for pharmaceutical excipients and antacid-related materials.
• Merck and other laboratory and pharmaceutical-raw-material distributors supplying catalog and qualified grades.
• Regional producers in China and India serving oral pharmaceutical and vaccine markets.
• Specialty chemical manufacturers supplying aluminum hydroxide for industrial and pharmaceutical applications.
• Distributors such as Brenntag and other regional pharmaceutical-ingredient distributors.

The supplier landscape is fragmented at the oral-grade level and more concentrated at the vaccine-adjuvant level. Concentration increases when the customer requires a documented history in licensed injectable products.

How does aluminum hydroxide compare with competing antacid excipients?

Aluminum hydroxide competes primarily with magnesium hydroxide, calcium carbonate, sodium bicarbonate, and combination formulations.

Attribute	Aluminum hydroxide	Magnesium hydroxide	Calcium carbonate	Sodium bicarbonate
Acid neutralization	Moderate	Moderate to high	High	Rapid
Typical formulation role	Antacid, suspension, gel	Antacid, laxative	Antacid, calcium source	Rapid antacid
Common tolerability issue	Constipation; aluminum exposure concerns	Diarrhea; magnesium exposure concerns	Gas, constipation, hypercalcemia risk	Sodium load, gas
Formulation format	Suspension, gel, tablet	Suspension, tablet	Chewable tablet, suspension	Tablet, powder, effervescent
Price sensitivity	High in commodity grades	High	High	High
Vaccine-adjuvant role	Established	Limited	Not a standard substitute	Not a standard substitute

Aluminum hydroxide remains commercially relevant because it can be combined with magnesium hydroxide to balance gastrointestinal side effects. It also has a separate, less substitutable role in vaccine adjuvants.

What is the FDA regulatory status of aluminum hydroxide?

Aluminum hydroxide has established regulatory use in both oral medicines and vaccines, but regulatory treatment depends on the product and grade.

Oral medicines

The FDA’s OTC monograph system identifies aluminum hydroxide as an active antacid ingredient under 21 C.F.R. Part 331. Products must meet the applicable conditions for active ingredients, labeling, dosage, combinations, and manufacturing controls.[1]

When sold as an excipient rather than as the therapeutic active ingredient, the material is subject to the drug manufacturer’s finished-product controls. The finished product sponsor must demonstrate that the excipient is suitable for its intended use and does not compromise quality, safety, or performance.

Vaccines

Aluminum hydroxide is used as an adjuvant in licensed vaccines. Vaccine manufacturers must control the adjuvant as part of the biologic manufacturing process and demonstrate consistency, safety, potency, stability, and performance to the FDA or other applicable regulator.[2]

Adjuvant status does not make every aluminum hydroxide grade interchangeable. A supplier’s material must meet the specifications and process requirements established for the vaccine product.

Compendial status

Pharmacopoeial monographs and general chapters provide identity, purity, assay, and quality requirements. USP-NF and European Pharmacopoeia standards are commercially important because pharmaceutical customers often specify compendial compliance in purchase and quality agreements.[3]

What is the Orange Book status of aluminum hydroxide?

Aluminum hydroxide generally does not have an Orange Book patent estate as an excipient. The FDA Orange Book lists approved drug products and associated patent and exclusivity information, not raw materials as standalone commercial substances.[4]

An aluminum hydroxide-containing antacid may be listed as an approved finished product, but that does not create patent protection for the excipient itself. Most OTC antacid products are subject to monograph regulation rather than a conventional new-drug patent strategy.

What patents protect aluminum hydroxide pharmaceutical products?

The core composition of aluminum hydroxide is old and is not realistically protected by a new composition-of-matter patent. Patent activity is more likely to concern:

• Particle-size distributions.
• Morphology and crystallinity.
• Surface modification.
• Aluminum hydroxide and antigen combinations.
• Vaccine-adjuvant formulations.
• Stable suspensions and gels.
• Combination antacid formulations.
• Manufacturing and purification methods.
• Sterile or low-endotoxin processing.
• Specific dosage forms and delivery systems.

Patent-expiration profile

The core substance has no meaningful remaining composition patent term. Relevant process or formulation patents may remain active in particular jurisdictions, but they are product-specific and cannot be inferred from the chemical name alone.

For commercial diligence, the relevant patent questions are:

1. Is the material sold as a generic excipient or under a proprietary product name?
2. Does the customer use the material in a patented vaccine formulation?
3. Is the supplier claiming a distinct morphology, surface chemistry, or manufacturing process?
4. Does the patent cover the excipient itself, the finished product, or only a method of use?
5. Are claims limited to the United States, Europe, China, India, or other markets?

Paragraph IV challenges and litigation

Paragraph IV litigation is generally not directed at aluminum hydroxide as a raw excipient. A generic applicant could challenge patents covering an aluminum hydroxide-containing finished drug, particularly a branded formulation or method of treatment. Such litigation would concern the finished product’s Orange Book-listed patents, not ordinary excipient supply.

The more relevant IP risk for suppliers is freedom to operate around proprietary adjuvant systems and manufacturing processes. Vaccine manufacturers may also protect antigen-adjuvant combinations, dosing schedules, and formulation stability rather than aluminum hydroxide itself.

Are biosimilar risks relevant to aluminum hydroxide?

Biosimilar risk is indirect. Aluminum hydroxide is not a biologic and cannot itself face biosimilar entry. Its commercial exposure arises from changes in biologic and vaccine manufacturing.

Biosimilar competition can create two opposing effects:

• Lower prices for some biologics may expand treatment volumes and increase demand for manufacturing inputs.
• Margin pressure may cause manufacturers to standardize formulations and qualify lower-cost adjuvant or excipient suppliers.

For vaccines, adjuvant demand depends on the product platform and regulatory approval. A biosimilar product does not automatically use aluminum hydroxide, and an adjuvant substitution may require substantial comparability data.

What manufacturing barriers protect aluminum hydroxide suppliers?

Manufacturing barriers are more important than patent barriers.

Technical barriers

A supplier must control precipitation, washing, drying, milling, suspension preparation, and packaging. Small changes can alter adsorption, viscosity, sedimentation, antigen binding, or finished-product stability.

Regulatory barriers

Pharmaceutical customers typically require:

• GMP compliance appropriate to the application.
• Detailed manufacturing and change-control documentation.
• Audit access.
• Traceability and deviation management.
• Validated analytical methods.
• Elemental impurity controls.
• Supplier qualification and periodic review.
• Stability data.
• Consistent site and process history.

Injectable applications impose higher requirements for microbial control, endotoxin, sterility assurance, and container compatibility.

Customer switching barriers

A formulation manufacturer can often switch oral-grade suppliers after testing and qualification. Vaccine manufacturers face a much higher switching burden because the adjuvant can affect antigen adsorption, potency, immunogenicity, and stability. This creates de facto customer lock-in even when the material is chemically generic.

How strong is the aluminum hydroxide patent and commercial estate?

The patent estate is weak at the substance level and stronger at the application level.

Estate component	Strength	Commercial implication
Core aluminum hydroxide composition	Low	Commodity exposure
Standard oral antacid use	Low to moderate	Limited exclusivity
Compendial pharmaceutical grade	Low patent protection	Quality and supply-chain competition
Engineered particle morphology	Moderate	Potential differentiation
Vaccine-adjuvant formulation	Moderate to strong	Product-specific protection
Manufacturing process	Moderate	Geographic and claim-scope dependent
GMP and regulatory history	Strong practical barrier	Supports retention and pricing
Licensed vaccine integration	Strong practical barrier	High switching costs

A supplier with only standard oral-grade powder has limited defensibility. A supplier with validated vaccine-adjuvant performance, regulatory history, and customer-specific technical data has a stronger commercial position even without broad patent exclusivity.

What is the financial trajectory for aluminum hydroxide suppliers?

The financial trajectory depends on product mix.

Commodity oral-grade trajectory

Revenue growth is likely to track:

• Generic antacid demand.
• Population growth and healthcare access.
• Regional OTC consumption.
• Raw-material, energy, and freight costs.
• Contract repricing.

Margins remain exposed to competition, particularly from producers with lower labor and energy costs. Volume growth may be positive while profit growth remains limited.

Vaccine-grade trajectory

Vaccine-grade demand has better structural economics. Revenue can grow through:

• New vaccine approvals.
• Expansion of existing vaccine capacity.
• Higher adjuvanted-vaccine penetration.
• Long-term supply agreements.
• Custom adjuvant development.
• Higher-value sterile or low-endotoxin products.

The main risk is customer concentration. A supplier may have a defensible position but still face a sharp revenue decline if a major vaccine program ends, changes formulation, or reduces production.

Public-company revenue exposure

Large diversified chemical and excipient companies generally do not disclose aluminum hydroxide revenue as a separate reporting line. Investors should avoid assigning total company revenue to the product category. A defensible estimate requires product-level sales, volume, average selling price, and gross-margin data that are usually available only through management disclosures, distributor data, or market research subscriptions.

The most useful financial indicators are:

• Share of sales from pharmaceutical and vaccine grades.
• Capacity utilization.
• Average selling price by grade.
• Long-term contract coverage.
• Customer concentration.
• Qualification pipeline.
• Regulatory inspection history.
• Raw-material and energy pass-through terms.
• Gross margin differential between oral and injectable grades.

What generic launch risks exist for aluminum hydroxide products?

Generic-entry risk is high for standard oral antacid products and lower for vaccine-adjuvant applications.

Oral products

A generic manufacturer can generally use aluminum hydroxide from multiple qualified sources, subject to finished-product requirements. Entry risks include:

• Need to match suspension behavior.
• Dissolution and assay requirements.
• Stability differences.
• Labeling and monograph compliance.
• Supplier qualification.
• Product-specific formulation patents.

These risks are usually manageable and do not create durable excipient exclusivity.

Vaccine products

Entry barriers are higher because the adjuvant is part of a complex biologic formulation. A competing manufacturer may need to reproduce:

• Antigen adsorption.
• Particle distribution.
• Surface charge.
• Dose and concentration.
• Release profile.
• Stability.
• Immunogenicity.
• Manufacturing consistency.

The result is a slower and more expensive substitution process.

What licensing deals and partnerships matter?

Licensing is more relevant to vaccine adjuvant systems than to standard aluminum hydroxide excipients. Companies may license:

• Proprietary adjuvant compositions.
• Vaccine platforms.
• Antigen-adjuvant combinations.
• Manufacturing know-how.
• Regional commercialization rights.
• Access to validated production sites.

Routine oral-grade aluminum hydroxide is normally purchased through supply agreements rather than high-value technology licenses. Vaccine programs can use development, supply, and commercialization agreements that create recurring demand but may impose exclusivity, minimum volumes, or geographic restrictions.

What geographic markets are most important?

Asia is central to both production and demand. China and India have significant pharmaceutical manufacturing capacity and growing vaccine production. North America and Europe remain important for high-specification, regulated, and vaccine-grade materials because customers place greater emphasis on documentation, inspection history, and change control.

Regional risks include:

• Import and export controls.
• Qualification of nonlocal manufacturing sites.
• Tariffs and freight costs.
• Local GMP enforcement.
• Concentration of production in a small number of facilities.
• Currency movements.
• Country-specific pharmacopoeial requirements.

A dual-source strategy is common for oral grades. Vaccine manufacturers may maintain fewer approved sources because each additional source increases comparability and regulatory work.

Key Takeaways

• Aluminum hydroxide is a mature excipient with limited substance-level patent protection.
• The largest volume market is oral antacid and suspension products.
• The strongest commercial economics are in vaccine-adjuvant and injectable grades.
• Regulatory history, GMP controls, particle engineering, and customer qualification are more important than core patents.
• Orange Book and Paragraph IV risks generally apply to finished drug products, not the excipient itself.
• Biosimilar risk is indirect and depends on changes in biologic or vaccine manufacturing.
• Commodity oral grades face price competition and relatively low switching costs.
• Vaccine-grade materials have higher margins, longer qualification cycles, and stronger customer retention.
• Public companies rarely disclose aluminum hydroxide revenue separately, so product-level financial exposure cannot be inferred from total company sales.
• The likely medium-term trajectory is stable volume growth with better profit potential from specialty, GMP, low-endotoxin, and vaccine-adjuvant grades.

FAQs

Is aluminum hydroxide an active pharmaceutical ingredient or an excipient?

It can be either. In antacid products, aluminum hydroxide is commonly the active ingredient. In other formulations, it is used as an excipient, adsorbent, stabilizer, or vaccine adjuvant.

Is aluminum hydroxide interchangeable between suppliers?

Not automatically. Oral grades may be interchangeable after qualification, but vaccine-adjuvant materials can differ substantially in particle morphology, adsorption, endotoxin, and biological performance.

Does aluminum hydroxide have a long patent life?

The core chemical substance does not have a meaningful remaining patent life. Protection may exist for specific formulations, particle characteristics, manufacturing methods, or vaccine applications.

Which aluminum hydroxide grade has the highest margin?

Vaccine-adjuvant and injectable GMP grades generally have higher margins than standard oral antacid grades because they require tighter specifications, technical support, validation, and regulatory qualification.

Can a generic manufacturer use a different aluminum hydroxide supplier?

Usually, subject to finished-product testing, supplier qualification, stability work, and regulatory requirements. The burden is substantially higher when the material is used in a licensed vaccine or complex biologic formulation.

References

1. U.S. Food and Drug Administration. (2024). Antacid products for over-the-counter human use: 21 C.F.R. Part 331. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-331

2. U.S. Food and Drug Administration. (2024). Vaccines licensed for use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines

3. United States Pharmacopeia. (2024). USP-NF: Aluminum hydroxide and pharmaceutical excipient standards. U.S. Pharmacopeial Convention. https://www.usp.org

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. World Health Organization. (2021). Manual for the production and control of vaccines: Adjuvants and vaccine formulation considerations. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality-assurance

6. Croda International Plc. (2023). Annual report and accounts 2023. https://www.croda.com/en-gb/investors/financial-information/annual-reports

7. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-11th-edition